| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, August 2008, p. 2926-2928, Vol. 52, No. 8
0066-4804/08/$08.00+0 doi:10.1128/AAC.00538-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Servicio de Micologia, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Madrid, Spain
Received 25 April 2008/ Returned for modification 12 May 2008/ Accepted 24 May 2008
In vitro susceptibility profiles of 58 Paecilomyces clinical isolates are reported. Amphotericin B, itraconazole, and echinocandins showed poor activity against Paecilomyces lilacinus, while the new triazoles were active against it. Paecilomyces variotii exhibited a different susceptibility pattern, being susceptible to most antifungal agents apart from voriconazole and ravuconazole.
Published ahead of print on 2 June 2008.
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |